Substance / Medication

Valsartan

Overview

Active Ingredient
valsartan
RxNorm CUI
69749
Labeler: AvKAREUpdated: 2026-02-25T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

5.1 () When pregnancy is detected, discontinue sacubitril and valsartan tablets as soon as possible 5.1 () Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus

Contraindications

When this intervention should not be used

5.2 [see Warnings and Precautions ()] 7.1 [see Drug Interactions ()] 7.1 [see Drug Interactions ()] Sacubitril and valsartan is contraindicated:• in patients with hypersensitivity to any component• in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy• with concom

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
The efficacy of Shenyankangfu tablets in combination with valsartan in diabetic nephropathy: A systematic review and meta-analysis.
Yang Yang, Zhang Xinyu, Yuan Yin et al. · Medicine (Baltimore) · 2025
PMID: 40020136Meta-AnalysisFull text (PMC)
The in-hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta-analysis.
Di Pietro Gianluca, Improta Riccardo, Severino Paolo et al. · ESC Heart Fail · 2025
PMID: 39473218Meta-AnalysisFull text (PMC)
Efficacy and safety of sacubitril-valsartan in hypertension patients with end-stage kidney disease on maintenance dialysis: a meta-analysis.
Nguyen Dung Viet, Pham Giang Thai, Pham Son Nguyen et al. · J Hypertens · 2025
PMID: 39927814Meta-Analysis
Effects of Sacubitril/Valsartan on Renal Function in Adults With Heart Failure: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Barboza Joshuan J, León-Figueroa Darwin A, Pasupuleti Vinay et al. · Heart Lung Circ · 2025
PMID: 40450497Meta-Analysis
Sacubitril/Valsartan Reduces the Risk of All-Cause Dementia in Patients with Heart Failure: A Systematic Review and Meta-Analysis.
Helal Mohamed Mohsen, Almosilhy Nereen A, Hamam Nada G et al. · Drugs Aging · 2025
PMID: 40728824Meta-Analysis
Sacubitril-Valsartan Lowers Atrial Fibrillation Recurrence and Left Atrial Volume Post-catheter Ablation: Systematic Review and Meta-Analysis.
de Lucena Larissa Araújo, Freitas Marcos Aurélio Araújo, Guida Camila Mota et al. · Am J Cardiovasc Drugs · 2025
PMID: 39470948Meta-Analysis
Sacubitril-valsartan in Cancer therapy-induced heart failure: A systematic review and meta-analysis of functional and hemodynamic parameters.
Hüntermann Ramon, Fischer-Bacca Caroline O, Alves Marcel F et al. · Curr Probl Cardiol · 2025
PMID: 39828108Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Valsartan (substance)
SNOMED CT
386876001
UMLS CUI
C0216784
RxNorm CUI
69749
Labeler
AvKARE

Clinical Data

This intervention maps to 10 entities in the Ltrl knowledge graph.

3
Conditions
4
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.